FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma-Reference-Cited by-同舟云学术

FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma

Published:2016-05-09 Issue:48 Volume:35 Page:6223-6234
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Li Y,Bouchlaka M N,Wolff J,Grindle K M,Lu L,Qian S,Zhong X,Pflum N,Jobin P,Kahl B S,Eickhoff J C,Wuerzberger-Davis S M,Miyamoto S,Thomas C J,Yang D T,Capitini C M,Rui L

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2016155.pdf

Reference55 articles.

1. Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416–3423.

2. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.

3. Chiorazzi N, Hatzi K, Albesiano E . B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. Ann N Y Acad Sci 2005; 1062: 1–12.

4. Kuppers R . Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251–262.

5. Kenkre VP, Kahl BS . The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways. Curr Hematol Malig Rep 2012; 7: 216–220.

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Blood;2024-08-22

2. Feedforward cysteine regulation maintains melanoma differentiation state and limits metastatic spread;Cell Reports;2024-07

3. Geranylgeranylated-SCF^FBXO10Regulates Selective Outer Mitochondrial Membrane Proteostasis and Function;2024-04-16

4. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma;Cell Reports Medicine;2024-04

5. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma;Blood;2023-11-30